NYMX Nymox Pharmaceutical Corporation

2.13
+0.03  (+1%)
Previous Close 2.1
Open 2.15
Price To Book 42.6
Market Cap 153,293,344
Shares 71,218,706
Volume 47,936
Short Ratio
Av. Daily Volume 226,979
Stock charts supplied by TradingView

NewsSee all news

  1. Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology

    HASBROUCK HEIGHTS, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that a new peer review report was published today in the World Journal of Urology,

  2. Nymox Announces New Appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs

    HASBROUCK HEIGHTS, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice

  3. Nymox Provides Update on Current Corporate Activities and Milestones

    HASBROUCK HEIGHTS, N.J., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to provide a current January 2020 update on several important corporate activities and achievements

  4. Nymox Announces New Peer Review Article on Fexapotide Pharmaco-Ablation Experimental Studies Published in Research and Reports in Urology

    HASBROUCK HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report a new peer review research report has been published on experimental studies of the

  5. Nymox Reports on Newly Issued Patents and Corporate Developments

    HASBROUCK HEIGHTS, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report very positive fundamental news, that the Company has received several new additional United

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Data released February 2016 met endpoint
NX-1207 long-term NX03-0040 trial
Low grade localized prostate cancer
NDA filing planned for 1H 2020.
NX-1207 Fexapotide
BPH

Latest News

  1. Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology

    HASBROUCK HEIGHTS, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that a new peer review report was published today in the World Journal of Urology,

  2. Nymox Announces New Appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs

    HASBROUCK HEIGHTS, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice

  3. Nymox Provides Update on Current Corporate Activities and Milestones

    HASBROUCK HEIGHTS, N.J., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to provide a current January 2020 update on several important corporate activities and achievements

  4. Nymox Announces New Peer Review Article on Fexapotide Pharmaco-Ablation Experimental Studies Published in Research and Reports in Urology

    HASBROUCK HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report a new peer review research report has been published on experimental studies of the

  5. Nymox Reports on Newly Issued Patents and Corporate Developments

    HASBROUCK HEIGHTS, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report very positive fundamental news, that the Company has received several new additional United